These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 10037008)

  • 1. Anti-tumour activity of bisphosphonates in human myeloma cells.
    Shipman CM; Rogers MJ; Apperley JF; Graham R; Russell G; Croucher PI
    Leuk Lymphoma; 1998 Dec; 32(1-2):129-38. PubMed ID: 10037008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates--mechanisms of action in multiple myeloma.
    Shipman CM; Rogers MJ; Vanderkerken K; Van Camp B; Graham R; Russell G; Croucher PI
    Acta Oncol; 2000; 39(7):829-35. PubMed ID: 11145441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates in multiple myeloma.
    Djulbegovic B; Wheatley K; Ross J; Clark O; Bos G; Goldschmidt H; Cremer F; Alsina M; Glasmacher A
    Cochrane Database Syst Rev; 2002; (3):CD003188. PubMed ID: 12137679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
    Gordon S; Helfrich MH; Sati HI; Greaves M; Ralston SH; Culligan DJ; Soutar RL; Rogers MJ
    Br J Haematol; 2002 Nov; 119(2):475-83. PubMed ID: 12406088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in multiple myeloma.
    Djulbegovic B; Wheatley K; Ross J; Clark O; Bos G; Goldschmidt H; Cremer F; Alsina M; Glasmacher A
    Cochrane Database Syst Rev; 2001; (4):CD003188. PubMed ID: 11687178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates in multiple myeloma.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2010 Mar; (3):CD003188. PubMed ID: 20238320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
    Shipman CM; Vanderkerken K; Rogers MJ; Lippitt JM; Asosingh K; Hughes DE; Van Camp B; Russell RG; Croucher PI
    Br J Haematol; 2000 Oct; 111(1):283-6. PubMed ID: 11091214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate therapy in multiple myeloma: past, present, future.
    Jantunen E
    Eur J Haematol; 2002; 69(5-6):257-64. PubMed ID: 12460229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bisphosphonates in the treatment of multiple myeloma].
    Stajszczyk M
    Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bone and myeloma].
    Ravaud P; Roux C
    Rev Prat; 1993 Feb; 43(3):293-7. PubMed ID: 8502958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapeutic targets in myeloma bone disease.
    Webb SL; Edwards CM
    Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates in multiple myeloma.
    Apperley JF; Croucher PI
    Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate anticancer activity in multiple myeloma.
    Terpos E
    Anticancer Agents Med Chem; 2012 Feb; 12(2):123-8. PubMed ID: 21864228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone complications in multiple myeloma.
    Berenson JR; Rajdev L; Broder M
    Cancer Biol Ther; 2006 Sep; 5(9):1082-5. PubMed ID: 16969119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
    Mhaskar R; Djulbegovic B
    JAMA; 2018 Oct; 320(14):1483-1484. PubMed ID: 30326511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.